Position in SEPN
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$1,272,820
New position
Shares Held
38,006
first reported quarter
Ownership
0.081%
of shares outstanding
% of Portfolio
0.05%
of 13F equity value
Holder Rank
#55
of 154 holders
Holding Since
Jun 2026
1 quarter on record
Voting authority
Sole 100%
Shared 0%
None 0%
Derivatives in SEPN
reported options exposure · as of Jun 30, 2026CallValue
$14,735,600
CallShares
440,000
PutValue
$6,698,000
PutShares
200,000
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Biotechnology
Healthcare · as of Jun 30, 2026Caption Management, LLC holds $249,760,911 across 78 Biotechnology names. SEPN ranks #38 (0.5% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | CGON |
CG Oncology, Inc.
|
484,461 | $34,420,954 | |
| 2 | INSM |
INSMED Inc
|
236,000 | $25,162,320 | |
| 3 | ERAS |
Erasca, Inc.
|
1,041,225 | $19,075,242 | |
| 4 | CELC |
Celcuity Inc.
|
170,000 | $17,785,400 | |
| 5 | DSGN |
Design Therapeutics, Inc.
|
1,118,098 | $16,178,878 | |
| 6 | MLYS |
Mineralys Therapeutics, Inc.
|
413,087 | $11,145,087 | |
| 7 | REPL |
Replimune Group, Inc.
|
783,873 | $8,677,474 | |
| 8 | TARS |
Tarsus Pharmaceuticals, Inc.
|
120,700 | $7,596,858 |
All Filings in SEPN
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,272,820 | 38,006 | Shares | Sole | 2026-08-14 | |
| 2026-06-30 | $14,735,600 | 440,000 | Call | Sole | 2026-08-14 | |
| 2026-06-30 | $6,698,000 | 200,000 | Put | Sole | 2026-08-14 | |
| No filing history on record for this holder in this stock. | ||||||